Industry Forecast: Controlled Release Drug Delivery Market to Generate $117.24 Billion Revenue by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Current and Projected Market Size of the Controlled Release Drug Delivery Industry?
Over the most recent years, the controlled release drug delivery market has seen a quick expansion. The market size is set to grow from $65.44 billion in 2024 to an estimated $72.34 billion in 2025, evidencing a compound annual growth rate (CAGR) of 10.5%. The historic growth of the market can be credited to factors such as the inception of innovative drug delivery systems, the introduction of early polymer-based formulations, the usage of microencapsulation techniques, the arrival of transdermal delivery, in addition to regulatory approvals and standardization.
Anticipated to witness significant expansion in the coming years, the controlled release drug delivery market’s valuation is predicted to reach $117.24 billion by 2029, with a considerable compound annual growth rate (CAGR) of 12.8%. This predicted growth during the forecast period can be ascribed to shifts towards customized medicine, the incorporation of advanced technology for improved patient comfort, the rise in biologics and biosimilars, market development in burgeoning regions, and advancements in the field of polymer science. The market is also likely to be shaped by trends such as the use of biodegradable and biocompatible materials, advancements in nanotechnology, personalized medicines and targeted therapies, advances in implantable medical devices, and innovations in encapsulation methodologies.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9930&type=smp
#Which Factors Are Currently Driving The Growth Of The Controlled Release Drug Delivery Market?
The proliferation of chronic diseases is anticipated to drive the controlled release drug delivery market’s expansion. Chronic diseases, also termed as noncommunicable diseases, comprise conditions such as heart disease, cancer, and diabetes diseases that last over a year and necessitate continuous medical care or impose limitations on daily activities, or both. Administering controlled-release drug delivery is imperative for chronic disease treatment. It is particularly significant for those living with chronic disorders that demand years of treatment or for individuals residing in areas with restricted resources and healthcare accessibility. Drug delivery systems enabling extended medication release are indispensable in such cases. For example, as per a September 2022 report from the World Health Organization (WHO), a health-focused agency based in Switzerland, chronic diseases account for the annual death of 41 million people, which constitutes 74% of the global death toll. Seventeen million people succumb to chronic diseases before reaching the age of 70. Furthermore, 77% of chronic disease-related deaths occur in low- and middle-income countries. These figures are projected to surge in the future. Consequently, the escalating occurrence of chronic diseases is fuelling the controlled release drug delivery market growth.
How Is The Global Controlled Release Drug Delivery Market Structured In Terms Of Segments?
The controlled release drug delivery market covered in this report is segmented –
1) By Technology: Wurster Technique, Coacervation, Micro Encapsulation, Implants, Transdermal, Targeted Delivery, Other Technologies
2) By Release Mechanism: Polymer Based Systems, Micro Reservoir Partition Controlled Drug Delivery Systems, Feedback Regulated Drug Delivery Systems, Activation-Modulated Drug Delivery Systems, Chemically Activated,
3) By Application: Metered Dose Inhalers, Injectable, Transdermal And Ocular Patches, Other Applications
4) By End User: Hospitals, Clinics, Personal, Research, Other End Users
Subsegments:
1) By Wurster Technique: Spray Coating, Fluid Bed Coating
2) By Coacervation: Simple Coacervation, Complex Coacervation
3) By Micro Encapsulation: Polymer-Based Micro Encapsulation, Lipid-Based Micro Encapsulation
4) By Implants: Biodegradable Implants, Non-Biodegradable Implants
5) By Transdermal: Microneedle Patches, Reservoir Systems, Matrix Systems
6) By Targeted Delivery: Nanoparticles, Antibody-Drug Conjugates, Liposomes
7) By Other Technologies: Osmotic Pumps, In Situ Gelling Systems
What Trends Are Currently Influencing Growth In The Controlled Release Drug Delivery Market?
The controlled-release drug delivery market is seeing a rise in technological innovation as a major trend. To secure their market positions, key companies in this sector are increasingly adopting novel technologies. In March 2022, for example, Evonik Industries AG, a pharmaceutical company based in Germany, introduced UDRATEC SoluFlow. This new microparticle technology enhances the solubility of active ingredients in oral drug formulations, offering a solution to solubility issues that conventional production methods fail to solve. EUDRATEC SoluFlow is an addition to the extensive portfolio of oral drug delivery solutions offered by Evonik Health Care, which includes oral excipients like EUDRAGIT functional polymers, ready-to-fill functional capsules such as EUDRACAPTM, and various other technologies and services aimed at enhancing drug performance.
Who Are The Main Participants Shaping The Controlled Release Drug Delivery Market Landscape?
Major companies operating in the controlled release drug delivery market include Johnson & Johnson Services Inc., Merck & Co. Inc., Alkermes plc, Coating Place Inc., Corium International Inc., Depomed Inc., Pfizer Inc., Aradigm Corporation, Capsugel LLC, GlaxoSmithKline plc, Bayer Healthcare LLC, Collegium Pharmaceuticals Inc., GE HealthCare Technologies Inc., Adare Pharmaceuticals Inc., Allergan plc, Novartis AG, Lonza Group AG, Colorcon Inc., SKY Pharmaceuticals Pvt. Ltd., AstraZeneca plc, Biogen Inc., Orbis Biosciences Inc., Alza Corporation, MicroCHIPS Inc., Endo International plc, Heron Therapeutics Inc., Intellipharmaceutics International Inc., Ipsen Biopharmaceuticals Inc., Luye Pharma Group Ltd., Medtronic plc, Nektar Therapeutics, Novo Nordisk A/S, Ocular Therapeutix Inc., Pacira BioSciences Inc., Progenity Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals Inc., Vectura Group plc, West Pharmaceutical Services Inc., Zosano Pharma Corporation, Zynerba Pharmaceuticals Inc.
Get The Full Report Here:
Which Region Currently Holds The Largest Share In The Controlled Release Drug Delivery Market?
North America was the largest region in the controlled release drug delivery market in 2024. The regions covered in the controlled release drug delivery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=9930&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
